A Phase 2 Study of Etirinotecan Pegol (NKTR-102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC)
Overview
- Phase
- Phase 2
- Intervention
- Pegylated Irinotecan
- Conditions
- Stage IV Non-small Cell Lung Cancer (NSCLC)
- Sponsor
- Joel Neal
- Enrollment
- 27
- Locations
- 1
- Primary Endpoint
- Central Nervous System (CNS) Disease Control Rate (Cohort A and C)
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
This phase 2 trial evaluates how well pegylated irinotecan (NKTR-102) works in treating patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or breast cancer (mBC) that has spread to the brain and does not respond to treatment. Pegylated irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Detailed Description
Primary Objective: For cohort A and Cohort C, to determine the central nervous system (CNS) disease control rate (number of patients with stable disease or partial response or complete response / total number of treated patients) at 12 weeks following treatment with etirinotecan pegol in patients with advanced non-small cell lung cancer (NSCLC) or with metastatic brain cancer (mBC) with refractory brain metastases Secondary Objectives: Cohorts A and C: * To measure the overall disease control rate and response rate for patients receiving study therapy * To measure the systemic (non-CNS) disease control rate and response rate for patients receiving study therapy * To observe the progression free survival of the study population * To observe the overall survival of the study population Cohort B: • To observe CNS and systemic disease control in small cell lung cancer (SCLC) Cohorts A, B and C: • To determine the safety profile of etirinotecan pegol
Investigators
Joel Neal
ASSISTANT PROFESSOR OF MEDICINE
Stanford University
Eligibility Criteria
Inclusion Criteria
- •At least 18 years of age.
- •Life expectancy of 3 months or longer.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or
- •Advanced or refractory cancer, consisting of
- •Metastatic breast cancer (mBC) for which single-agent cytotoxic chemotherapy is indicated. OR
- •Histologically-proven metastatic lung cancer:
- •Non-small cell lung cancer (NSCLC) as Stage IV disease or recurrent metastatic disease \[per lung cancer tumor, node and metastasis (TNM) classification system, 7th ed\] (Cohort A) OR
- •Small cell lung cancer (SCLC) as extensive stage or recurrent metastatic disease (cohort B), including tumors with mixed small cell and non-small cell elements.
- •Prior chemotherapy (at least one of the following):
- •At least one line of prior systemic chemotherapy
Exclusion Criteria
- •Previous treatment with a camptothecin derivative (eg, irinotecan, topotecan, and investigational agents including but not limited to exatecan, rubitecan, gimatecan, karenitecin, SN38 investigational agents, EZN 2208, SN 2310, and AR 67) is not allowed
- •Patients may not have a known history of leptomeningeal disease, as diagnosed by positive CSF cytology, unless prospective permission for enrollment is granted from the sponsor and the PI
- •Patients may not have had major surgery or radiotherapy (therapeutic and/or palliative) within 14 days prior to initiation of study treatment, including CNS-directed radiation therapy. Minor procedures, such as tumor biopsy, thoracentesis, or intravenous catheter placement are allowed with no waiting period
- •Patients may not have the following co morbid disease or concurrent illness:
- •Chronic or acute gastrointestinal (GI) disorders resulting in diarrhea of any severity grade; patients may not use chronic anti-diarrheal supportive care (more than 3 days/week) to control diarrhea in the 28 days prior to first dose of investigational drug. (exception: anti-diarrheal medications used to control symptoms from a medication that will be discontinued prior to study are allowed with a 7 day washout before study therapy, for example loperamide for erlotinib-associated diarrhea)
- •Known cirrhosis, defined as Child Pugh class A or higher liver disease
- •Other active malignancy, except for non melanoma skin cancer and carcinoma in situ (of the cervix or bladder)
- •Any other severe/uncontrolled inter current illness or significant co morbid conditions that in the opinion of the investigator would impair study participation or cooperation
- •Patients may not have a known allergy or hypersensitivity to any of the components of the investigational therapy, including polyethylene glycol (PEG) or topoisomerase inhibitors
- •Patients may not be receiving the following medications at the time of first dose of investigational drug:
Arms & Interventions
Cohort A - Pegylated Irinotecan to treat NSCLC
Patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
Intervention: Pegylated Irinotecan
Cohort B - Pegylated Irinotecan to treat SCLC
Patients with small cell lung carinoma (SCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
Intervention: Pegylated Irinotecan
Cohort C - Pegylated Irinotecan to treat mBC
Patients with metastatic breast cancer (MBC) to brain will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
Intervention: Pegylated Irinotecan
Outcomes
Primary Outcomes
Central Nervous System (CNS) Disease Control Rate (Cohort A and C)
Time Frame: At 12 weeks
Central nervous system (CNS) disease control (DC) is defined as a complete response (CR); partial response (PR); or stable disease (SD). The outcome is reported as the number and percentage of participants who achieve DC, a number without dispersion. Response criteria are as follows. Note that any lesion less than 10 mm in longest diameter (LD) is considered unchanged unless there is a ≥ 3 mm change in the sum of the LDs. * CR = Disappearance of all target lesions, sustained for ≥ 4 weeks with no new lesions; clinical condition stable or improved * PR = ≥ 30% decrease in target lesion LD and no new lesions, sustained for ≥ 4 weeks; clinical condition stable or improved * PD (progressive disease) = Any of 20% increase in target lesion LD; increase in T2/FLAIR non-enhancing lesions; any new lesions; non-target progression; or clinical deterioration * SD = Neither PR or PD
Secondary Outcomes
- Overall Disease Control Rate (Cohort A and C)(At 12 weeks)
- Overall Survival (Cohort A and C)(4 years)
- Systemic Disease Control (Cohort B)(At 12 weeks)
- Related Adverse Events (Toxicity)(Up to 2 years)
- Overall Response Rate (Cohort A and C)(At 12 weeks)
- Systemic (Non-CNS) Disease Control Rate (Cohort A and C)(At 12 weeks)
- Progression-free Survival (PFS) (Cohort A and C)(Date of first dose of pegylated irinotecan NKTR 102 to date of disease progression, assessed up to 2 years)
- Systemic (Non-CNS) Response Rate (Cohort A and C)(At 12 weeks)
- Central Nervous System (CNS) Disease Control (Cohort B)(At 12 weeks)